Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Saturn Oil & Gas Inc. Announces its First Development of Cardium Wells at Brazeau and Continued Successful Development (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Scorpius Holdings Inc SCPX

Healthcare Biotechnology
Scorpius Holdings, Inc., formerly NightHawk Biosciences, Inc., is an integrated contract development and manufacturing company. The Company is focused on advancing biologic and cell therapy programs to the clinic and beyond. It offers a broad array of analytical testing, process development, and manufacturing services to pharmaceutical and biotech companies at its facilities in San Antonio... see more

Recent & Breaking News (NYSEAM:SCPX)

Heat Biologics Announces Research Collaboration with University of Miami to Develop Vaccine Designed to Protect Against COVID-19 Coronavirus

Accesswire March 5, 2020

Heat Biologics CEO to Appear Today on ABC11-WTVD to Discuss the Company's Newly Launched Program to Develop a Vaccine to Protect Against SARS-CoV-2 Coronavirus that Causes COVID-19

Accesswire March 4, 2020

Heat Biologics Launches Program to Develop Vaccine Designed to Protect Against COVID-19 Coronavirus

Accesswire March 3, 2020

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Heat Biologics, Inc.- HTBX

ACCESSWIRE IA February 28, 2020

Heat Biologics, Inc. Announces Closing of $7,000,000 Public Offering

Accesswire January 21, 2020

Heat Biologics, Inc. Prices $7,000,000 Public Offering

Accesswire January 16, 2020

Heat Biologics Announces Additional Positive Top Line Phase 2 Data of HS-110 plus Nivolumab in Advanced NSCLC Patients

Accesswire November 20, 2019

Heat Biologics Announces Additional Top Line Phase 2 Data of HS-110 plus Nivolumab in Advanced NSCLC Patients at AACR Tumor Immunology and Immunotherapy Conference

Accesswire November 18, 2019

Heat Biologics Reports Third Quarter 2019 Results and Provides Corporate Update

Accesswire November 15, 2019

Heat Biologics Presents Additional Phase 2 Interim Data in Advanced NSCLC Patients at the SITC 34th Annual Meeting

Accesswire November 11, 2019

Heat Biologics Announces a Poster Presentation of Updated Top Line Phase 2 Data of HS-110 plus Nivolumab after Checkpoint Inhibitor Treatment Failure in NSCLC Patients at the SITC 34th Annual Meeting

Accesswire October 24, 2019

Heat Biologics Reports Second Quarter 2019 Results and Provides Corporate Update

Accesswire August 14, 2019

Heat Biologics Announces FDA Clearance of IND Application to Begin Phase 1 Trial of HS-130 in Combination with Heat's HS-110

Accesswire August 12, 2019

Heat Biologics CEO and Lead Director to Participate in German Investor Forums

Accesswire August 7, 2019

Heat Biologics Completes Enrollment in Phase 2 Non-Small Cell Lung Cancer Trial

Accesswire July 9, 2019

Heat Biologics Announces Promising Interim Phase 2 Lung Cancer Data Suggesting that HS-110 Plus Nivolumab May Restore Clinical Benefit After Checkpoint Inhibitor Treatment Failure

Accesswire June 3, 2019

Heat Biologics to Present at the 20th Annual B. Riley FBR Institutional Investor Conference

Accesswire May 20, 2019

Heat Biologics Reports First Quarter 2019 Results and Provides Corporate Update

Accesswire May 15, 2019

Heat Biologics Lead Director to Present at the ChinaBio 2019 Conference in Shanghai

Accesswire May 6, 2019

Heat Biologics CEO to Present at the ThinkEquity Conference in New York City

Accesswire April 18, 2019